A single case reports thrombocytopenia with thrombosis syndrome (TTS) following the mRNA-1273 vaccine for COVID-19. Previously, it was hypothesized that adenoviral vector-based vaccines were the sole cause of TTS or vaccine-induced TTS (VITT). The case is published in Annals of Internal Medicine.

Researchers from Allegheny Health Network, Pittsburgh, Pennsylvania report the case of a 65-year-old man with chronic hypertension and hyperlipidemia who presented to the hospital with 1 week of bilateral lower-extremity discomfort, intermittent headaches, and 2 days of dyspnea 10 days after receiving a second dose of the mRNA-1273 vaccine. The patient had no known exposure to heparin, a medication that has been associated with TTS. They were unable to identify other causes of TTS, including SARS CoV-2 infection, other concurrent infections, immune thrombocytopenia, or thrombotic thrombocytopenic purpura, leading the investigators to conclude that the diagnosis might be VITT, as defined by the Centers for Disease Control and Prevention and the Brighton Collaboration. Despite rapid and exhaustive treatment, the patient died.

Source: Read Full Article